Virginia Fernández‐Redondo

Virginia Fernández‐Redondo

Auto-generated profile, based on publicly available information

Virginia Fernández‐Redondo

Department of Dermatology, Complejo Hospitalario Universitario, Faculty of Medicine, Santiago de Compostela, Spain

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2012 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
Wolfgang UterWolfgang Uter
Wolfgang Uter
WAWerner Aberer
Werner Aberer
José C. Armario-HitaJosé C. Armario-Hita
José C. Armario-Hita
JFJosé M. Fernandez‐Vozmediano
José M. Fernandez‐Vozmediano
FAFabio Ayala
Fabio Ayala
ASAxel Schnuch
Axel Schnuch

19 January 2010 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
JGJuan García‐Gavín
Juan García‐Gavín
DGDaniel González‐Vilas
Daniel González‐Vilas
VFVirginia Fernández‐Redondo
Virginia Fernández‐Redondo
JTJaime Toribio
Jaime Toribio

15 February 2012 in Leukemia
Verified
Journal Article
Open access
PDF file
BPB Paiva
B Paiva
Norma C. GutiérrezNorma C. Gutiérrez
Norma C. Gutiérrez
XCX Chen
X Chen
MVMaría-Belén Vidriales
María-Belén Vidriales
MMM-Á Montalbán
M-Á Montalbán
OGon behalf of the GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study groups
on behalf of the GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study groups
The presence of CD19 in myelomatous plasma cells (MM-PCs) correlates with adverse prognosis in multiple myeloma (MM). Although CD19 expression is upregulated by CD81, this marker has been poorly investigated and its prognostic value in MM remains unknown. We have analyzed CD81 expression by multiparameter flow cytometry in MM-PCs from 230 MM patients at diagnosis included in the Grupo Español de Mieloma (GEM)05>65years trial as well as 56 high-risk smoldering MM (SMM). CD81 expression was detected in 45% (103/230) MM patients, and the detection of CD81+ MM-PC was an independent prognostic factor for progression-free (hazard ratio=1.9; P=0.003) and overall survival (hazard ratio=2.0; P=0.02); this adverse impact was validated in an additional series of 325 transplant-candidate MM patients included in the GEM05 <65 years trial. Moreover, CD81+ SMM (n=34/56, 57%) patients had a shorter time to progression to MM (P=0.02). Overall, our results show that CD81 may have a relevant role in MM pathogenesis and represent a novel adverse prognostic marker in myeloma.

29 November 2016 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
GDGustavo Deza
Gustavo Deza
BGBegoña García‐Bravo
Begoña García‐Bravo
JSJuan F. Silvestre
Juan F. Silvestre
MPMaria A. Pastor‐Nieto
Maria A. Pastor‐Nieto
RGRicardo González‐Pérez
Ricardo González‐Pérez
GEGeidac
Geidac

1 July 2013 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Open access
LPLuis Puig
Luis Puig
JCJ.M. Carrascosa
J.M. Carrascosa
IBI. Belinchón
I. Belinchón
VFV. Fernández-Redondo
V. Fernández-Redondo
GCG. Carretero
G. Carretero
MRM. Ribera
M. Ribera
Topical therapy is key to the successful management of psoriasis, and patient adherence to treatment contributes to its effectiveness in the long-term. To establish consensus on adherence to topical treatment in psoriasis, draw up recommendations on how adherence could be improved, and evaluate the properties of the main vehicles used. We designed a questionnaire on adherence to topical treatments in psoriasis and another on the properties of the main vehicles used; the 2 questionnaires were evaluated using the Delphi method by a panel of experts and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology, respectively. Consensus was reached on the following statements: a) treatment adherence increases the effectiveness of topical treatments in psoriasis; b) to improve adherence, it is necessary to improve communication between patients and health care staff, provide written instructions, and simplify treatment with easy-to-use, pleasant products that are preferably applied only once a day; c) treatment satisfaction increases adherence and tends to improve the health-related quality of life of the patient. Ointment was rated the worst vehicle, while foams and solutions were rated the best. Creams and lipophilic gels were considered to be better than ointment in several respects. To improve adherence to topical regimens in psoriasis and the effectiveness of such therapy, we need to give patients more information, simplify treatment regimens, and prescribe easy-to-use products that will ensure satisfaction.

10 July 2006 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
MCMiguel Cabanillas
Miguel Cabanillas
VFVirginia Fernández‐Redondo
Virginia Fernández‐Redondo
JTJaime Toribio
Jaime Toribio